Browse > Article
http://dx.doi.org/10.14348/molcells.2019.0038

Knockdown of Pyruvate Kinase M Inhibits Cell Growth and Migration by Reducing NF-κB Activity in Triple-Negative Breast Cancer Cells  

Ma, Chaobing (Department of Breast Surgery, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou University)
Zu, Xueyin (China-US (Henan) Hormel Cancer Institute)
Liu, Kangdong (China-US (Henan) Hormel Cancer Institute)
Bode, Ann M. (The Hormel Institute, University of Minnesota)
Dong, Zigang (The Hormel Institute, University of Minnesota)
Liu, Zhenzhen (Department of Breast Surgery, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou University)
Kim, Dong Joon (China-US (Henan) Hormel Cancer Institute)
Publication Information
Molecules and Cells / v.42, no.9, 2019 , pp. 628-636 More about this Journal
Abstract
Altered genetic features in cancer cells lead to a high rate of aerobic glycolysis and metabolic reprogramming that is essential for increased cancer cell viability and rapid proliferation. Pyruvate kinase muscle (PKM) is a rate-limiting enzyme in the final step of glycolysis. Herein, we report that PKM is a potential therapeutic target in triple-negative breast cancer (TNBC) cells. We found that PKM1 or PKM2 is highly expressed in TNBC tissues or cells. Knockdown of PKM significantly suppressed cell proliferation and migration, and strongly reduced S phase and induced G2 phase cell cycle arrest by reducing phosphorylation of the CDC2 protein in TNBC cells. Additionally, knockdown of PKM significantly suppressed $NF-{\kappa}B$ (nuclear factor kappa-light-chain-enhancer of activated B cells) activity by reducing the phosphorylation of p65 at serine 536, and also decreased the expression of $NF-{\kappa}B$ target genes. Taken together, PKM is a potential target that may have therapeutic implications for TNBC cells.
Keywords
cell cycle; $NF-{\kappa}B$; PKM1; PKM2; triple-negative breast cancer cells;
Citations & Related Records
연도 인용수 순위
  • Reference
1 House, C.D., Grajales, V., Ozaki, M., Jordan, E., Wubneh, H., Kimble, D.C., James, J.M., Kim, M.K., and Annunziata, C.M. (2018). $IKK_\varepsilon$ cooperates with either MEK or non-canonical NF-kB driving growth of triple-negative breast cancer cells in different contexts. BMC Cancer 18, 595.   DOI
2 Israel, A. (2010). The IKK complex, a central regulator of NF-kappaB activation. Cold Spring Harb. Perspect. Biol. 2, a000158.   DOI
3 Ito-Kureha, T., Koshikawa, N., Yamamoto, M., Semba, K., Yamaguchi, N., Yamamoto, T., Seiki, M., and Inoue, J. (2015). Tropomodulin 1 expression driven by NF-kappaB enhances breast cancer growth. Cancer Res. 75, 62-72.   DOI
4 Kim, D.J., Park, Y.S., Kang, M.G., You, Y.M., Jung, Y., Koo, H., Kim, J.A., Kim, M.J., Hong, S.M., Lee, K.B., et al. (2015). Pyruvate kinase isoenzyme M2 is a therapeutic target of gemcitabine-resistant pancreatic cancer cells. Exp. Cell Res. 336, 119-129.   DOI
5 King, A. and Gottlieb, E. (2009). Glucose metabolism and programmed cell death: an evolutionary and mechanistic perspective. Curr. Opin. Cell Biol. 21, 885-893.   DOI
6 Kroemer, G. and Pouyssegur, J. (2008). Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13, 472-482.   DOI
7 Kuo, W.Y., Hwu, L., Wu, C.Y., Lee, J.S., Chang, C.W., and Liu, R.S. (2017). STAT3/NF-kappaB-regulated lentiviral TK/GCV suicide gene therapy for Cisplatin-resistant triple-negative breast cancer. Theranostics 7, 647-663.   DOI
8 Lebert, J.M., Lester, R., Powell, E., Seal, M., and McCarthy, J. (2018). Advances in the systemic treatment of triple-negative breast cancer. Curr. Oncol. 25(Suppl 1), S142-S150.   DOI
9 Luo, W., Hu, H., Chang, R., Zhong, J., Knabel, M., O'Meally, R., Cole, R.N., Pandey, A., and Semenza, G.L. (2011). Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 145, 732-744.   DOI
10 Luo, W. and Semenza, G.L. (2011). Pyruvate kinase M2 regulates glucose metabolism by functioning as a coactivator for hypoxia-inducible factor 1 in cancer cells. Oncotarget 2, 551-556.   DOI
11 Morita, M., Sato, T., Nomura, M., Sakamoto, Y., Inoue, Y., Tanaka, R., Ito, S., Kurosawa, K., Yamaguchi, K., Sugiura, Y., et al. (2018). PKM1 confers metabolic advantages and promotes cell-autonomous tumor cell growth. Cancer Cell 33, 355-367.e7.   DOI
12 Lv, L., Li, D., Zhao, D., Lin, R., Chu, Y., Zhang, H., Zha, Z., Liu, Y., Li, Z., Xu, Y., et al. (2011). Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth. Mol. Cell 42, 719-730.   DOI
13 Mazurek, S. (2007). Pyruvate kinase type M2: a key regulator within the tumour metabolome and a tool for metabolic profiling of tumours. Ernst Schering Found. Symp. Proc. (4), 99-124.
14 Mazurek, S. (2011). Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int. J. Biochem. Cell Biol. 43, 969-980.   DOI
15 Nabel, G.J. and Verma, I.M. (1993). Proposed NF-kappa B/I kappa B family nomenclature. Genes Dev. 7, 2063.   DOI
16 Okazaki, M., Fushida, S., Tsukada, T., Kinoshita, J., Oyama, K., Miyashita, T., Ninomiya, I., Harada, S., and Ohta, T. (2018). The effect of HIF-1alpha and PKM1 expression on acquisition of chemoresistance. Cancer Manag. Res. 10, 1865-1874.   DOI
17 Qiao, Y., He, H., Jonsson, P., Sinha, I., Zhao, C., and Dahlman-Wright, K. (2016). AP-1 is a key regulator of Proinflammatory cytokine TNFalphamediated triple-negative breast cancer progression. J. Biol. Chem. 291, 5068-5079.   DOI
18 Tennant, D.A., Duran, R.V., Boulahbel, H., and Gottlieb, E. (2009). Metabolic transformation in cancer. Carcinogenesis 30, 1269-1280.   DOI
19 Tutt, A., Tovey, H., Cheang, M.C.U., Kernaghan, S., Kilburn, L., Gazinska, P., Owen, J., Abraham, J., Barrett, S., Barrett-Lee, P., et al. (2018). Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat. Med. 24, 628-637.   DOI
20 Tennant, D.A., Duran, R.V., and Gottlieb, E. (2010). Targeting metabolic transformation for cancer therapy. Nat. Rev. Cancer 10, 267-277.   DOI
21 Vander Heiden, M.G., Cantley, L.C., and Thompson, C.B. (2009). Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029-1033.   DOI
22 Wang, H.J., Hsieh, Y.J., Cheng, W.C., Lin, C.P., Lin, Y.S., Yang, S.F., Chen, C.C., Izumiya, Y., Yu, J.S., Kung, H.J., et al. (2014). JMJD5 regulates PKM2 nuclear translocation and reprograms HIF-1alpha-mediated glucose metabolism. Proc. Natl. Acad. Sci. U. S. A. 111, 279-284.   DOI
23 Wu, X., Zahari, M.S., Ma, B., Liu, R., Renuse, S., Sahasrabuddhe, N.A., Chen, L., Chaerkady, R., Kim, M.S., Zhong, J., et al. (2015). Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways. Oncotarget 6, 29143-29160.   DOI
24 Yamaguchi, N., Ito, T., Azuma, S., Ito, E., Honma, R., Yanagisawa, Y., Nishikawa, A., Kawamura, M., Imai, J., Watanabe, S., et al. (2009). Constitutive activation of nuclear factor-kappaB is preferentially involved in the proliferation of basal-like subtype breast cancer cell lines. Cancer Sci. 100, 1668-1674.   DOI
25 Yang, W., Xia, Y., Hawke, D., Li, X., Liang, J., Xing, D., Aldape, K., Hunter, T., Alfred Yung, W.K., and Lu, Z. (2012a). PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell 150, 685-696.   DOI
26 Bianchini, G., Balko, J.M., Mayer, I.A., Sanders, M.E., and Gianni, L. (2016). Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat. Rev. Clin. Oncol. 13, 674-690.   DOI
27 Anastasiou, D., Poulogiannis, G., Asara, J.M., Boxer, M.B., Jiang, J.K., Shen, M., Bellinger, G., Sasaki, A.T., Locasale, J.W., Auld, D.S., et al. (2011). Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science 334, 1278-1283.   DOI
28 Azoitei, N., Becher, A., Steinestel, K., Rouhi, A., Diepold, K., Genze, F., Simmet, T., and Seufferlein, T. (2016). PKM2 promotes tumor angiogenesis by regulating HIF-1alpha through NF-kappaB activation. Mol. Cancer 15, 3.
29 Barbie, T.U., Alexe, G., Aref, A.R., Li, S., Zhu, Z., Zhang, X., Imamura, Y., Thai, T.C., Huang, Y., Bowden, M., et al. (2014). Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth. J. Clin. Invest. 124, 5411-5423.   DOI
30 Yang, W., Zheng, Y., Xia, Y., Ji, H., Chen, X., Guo, F., Lyssiotis, C.A., Aldape, K., Cantley, L.C., and Lu, Z. (2012b). ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat. Cell Biol. 14, 1295-1304.   DOI
31 Zhou, Z., Li, M., Zhang, L., Zhao, H., Sahin, O., Chen, J., Zhao, J.J., Songyang, Z., and Yu, D. (2018). Oncogenic kinase-induced PKM2 tyrosine 105 phosphorylation converts nononcogenic PKM2 to a tumor promoter and induces cancer stem-like cells. Cancer Res. 78, 2248-2261.   DOI
32 Dang, C.V. (2012). Links between metabolism and cancer. Genes Dev. 26, 877-890.   DOI
33 Bonotto, M., Gerratana, L., Poletto, E., Driol, P., Giangreco, M., Russo, S., Minisini, A.M., Andreetta, C., Mansutti, M., Pisa, F.E., et al. (2014). Measures of outcome in metastatic breast cancer: insights from a real-world scenario. Oncologist 19, 608-615.   DOI
34 Chaneton, B. and Gottlieb, E. (2012). Rocking cell metabolism: revised functions of the key glycolytic regulator PKM2 in cancer. Trends Biochem. Sci. 37, 309-316.   DOI
35 Chang, B., Sokhn, J., James, E., and Abu-Khalaf, M. (2014). Prolonged progression-free survival in a patient with triple-negative breast cancer metastatic to the liver after chemotherapy and local radiation therapy. Clin. Breast Cancer 14, e61-e64.   DOI
36 Chiavarina, B., Whitaker-Menezes, D., Martinez-Outschoorn, U.E., Witkiewicz, A.K., Birbe, R., Howell, A., Pestell, R.G., Smith, J., Daniel, R., Sotgia, F., et al. (2011). Pyruvate kinase expression (PKM1 and PKM2) in cancer-associated fibroblasts drives stromal nutrient production and tumor growth. Cancer Biol. Ther. 12, 1101-1113.   DOI
37 Christofk, H.R., Vander Heiden, M.G., Harris, M.H., Ramanathan, A., Gerszten, R.E., Wei, R., Fleming, M.D., Schreiber, S.L., and Cantley, L.C. (2008). The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452, 230-233.   DOI
38 DeBerardinis, R.J., Lum, J.J., Hatzivassiliou, G., and Thompson, C.B. (2008). The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 7, 11-20.   DOI
39 Gao, X., Wang, H., Yang, J.J., Liu, X., and Liu, Z.R. (2012). Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. Mol. Cell 45, 598-609.   DOI
40 Fantin, V.R., St-Pierre, J., and Leder, P. (2006). Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9, 425-434.   DOI
41 Han, D., Wei, W., Chen, X., Zhang, Y., Wang, Y., Zhang, J., Wang, X., Yu, T., Hu, Q., Liu, N., et al. (2015). NF-kappaB/RelA-PKM2 mediates inhibition of glycolysis by fenofibrate in glioblastoma cells. Oncotarget 6, 26119-26128.   DOI
42 Harris, I., McCracken, S., and Mak, T.W. (2012). PKM2: a gatekeeper between growth and survival. Cell Res. 22, 447-449.   DOI
43 Hayden, M.S. and Ghosh, S. (2008). Shared principles in NF-kappaB signaling. Cell 132, 344-362.   DOI